{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T04:02:52Z","timestamp":1746417772366,"version":"3.40.4"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>Pembrolizumab, a monoclonal antibody targeting programmed cell death-1 (PD-1), is approved as a therapy for unresectable or metastatic melanoma. Immunotherapy-associated pneumonitis is an uncommon event.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 73-year-old man was admitted to our hospital with a history of melanoma on the left side of the face (resected in December 2012) and metastasis to the left lung upper lobe (resected in November 2016). Recurrence of metastasis to the bilateral lungs and left pleura was detected in April 2018. A complete response was achieved following treatment with pembrolizumab, with lower limb rashes the only adverse events occurring during therapy. The patient was readmitted in March 2019 with a productive cough, shortness of breath, and mild fever, and sputum culture identified <jats:italic toggle=\"yes\">Escherichia coli<\/jats:italic>.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>A diagnosis of pneumonia was made, and although cough and shortness of breath responded to ceftazidime and levofloxacin, but fever and poor appetite persisted. Computed tomography showed no improvement in the bilateral lower lobe lesions. Prednisone was initiated based on a clinical diagnosis of immunotherapy-related pneumonitis. The response to prednisone confirmed the diagnosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The patient first received ceftazidime and levofloxacin, but the symptoms persisted. Prednisone was initiated based on a clinical diagnosis of immunotherapy-related pneumonitis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcome:<\/jats:title>\n            <jats:p>Complete resolution of the bilateral lung lesions occurred after 45 days of prednisone therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>This case report highlights that both pneumonitis and bacterial pneumonia can occur as complications of anti-PD-1 immunotherapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000024018","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:37:08Z","timestamp":1610584628000},"page":"e24018","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Immunotherapy-related pneumonitis and bacterial pneumonia after the successful treatment of metastatic malignant melanoma with pembrolizumab"],"prefix":"10.1097","volume":"100","author":[{"given":"Qin","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,1,8]]},"reference":[{"key":"R1-20250504","first-page":"591","article-title":"Vital signs: melanoma incidence and mortality trends and projections \u2013 United States, 1982\u20132030","volume":"64","author":"Guy","year":"2015","journal-title":"Morb Mortal Wkly Rep"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"57","DOI":"10.21037\/cco.2015.12.02","article-title":"Chinese guidelines on the diagnosis and treatment of melanoma (2015 edition)","volume":"5","author":"Guo","year":"2016","journal-title":"Chin Clin Oncol"},{"issue":"(Suppl 1)","key":"R3-20250504","first-page":"S78","article-title":"Melanoma survival in the United States, 1992 to 2005","volume":"65","author":"Pollack","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1002\/ijc.30407","article-title":"Epidemiology of cutaneous melanoma in Sweden-Stage-specific survival and rate of recurrence","volume":"139","author":"Rockberg","year":"2016","journal-title":"Int J Cancer"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1080\/21645515.2016.1190889","article-title":"Advances in immunotherapy for melanoma management","volume":"12","author":"Dany","year":"2016","journal-title":"Hum Vaccines Immunother"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1158\/1078-0432.CCR-16-0664","article-title":"FDA approval summary: pembrolizumab for the treatment of patients with unresectable or metastatic melanoma","volume":"23","author":"Barone","year":"2017","journal-title":"Clin Cancer Res: an official journal of the American Association for Cancer Research"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.tranon.2019.02.007","article-title":"A phase Ib study of pembrolizumab as second-line therapy for Chinese patients with advanced or metastatic melanoma (KEYNOTE-151)","volume":"12","author":"Si","year":"2019","journal-title":"Transl Oncol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann Oncol: official journal of the European Society for Medical Oncology"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.18.00204","article-title":"Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial","volume":"37","author":"Kluger","year":"2019","journal-title":"J Clin Oncol: official journal of the American Society of Clinical Oncology"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"e16542","DOI":"10.1097\/MD.0000000000016542","article-title":"Real-world experience with pembrolizumab in patients with advanced melanoma: a large retrospective observational study","volume":"98","author":"Liu","year":"2019","journal-title":"Medicine"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"Mmt05","DOI":"10.2217\/mmt-2017-0028","article-title":"Real-world experience with pembrolizumab toxicities in advanced melanoma patients: a single-center experience in the UK","volume":"5","author":"So","year":"2018","journal-title":"Melanoma Manag"},{"key":"R14-20250504","first-page":"86","article-title":"Pembrolizumab utilization and outcomes for advanced melanoma in US Community Oncology Practices","volume":"41","author":"Cowey","year":"2018","journal-title":"J Immunother (Hagerstown, Md: 1997)"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s13046-019-1266-0","article-title":"Advances in cancer immunotherapy 2019 \u2013 latest trends","volume":"38","author":"Kruger","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/s41591-018-0134-3","article-title":"Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab","volume":"24","author":"Gandara","year":"2018","journal-title":"Nat Med"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1001\/jamaoncol.2018.7098","article-title":"Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non-small cell lung cancer with use of a next-generation sequencing cancer gene panel","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol: official journal of the European Society for Medical Oncology"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","article-title":"Toxicities of immunotherapy for the practitioner","volume":"33","author":"Weber","year":"2015","journal-title":"J Clin Oncol: official journal of the American Society of Clinical Oncology"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol: official journal of the American Society of Clinical Oncology"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fimmu.2019.00108","article-title":"Risk of pneumonitis and pneumonia associated with immune checkpoint inhibitors for solid tumors: a systematic review and meta-analysis","volume":"10","author":"Su","year":"2019","journal-title":"Front Immunol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"e16158","DOI":"10.1097\/MD.0000000000016158","article-title":"Pneumonitis and concomitant bacterial pneumonia in patients receiving pembrolizumab treatment: three case reports and literature review","volume":"98","author":"Jun","year":"2019","journal-title":"Medicine"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000024018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:26:18Z","timestamp":1746339978000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000024018"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2021,1,8]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000024018","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2021,1,8]]},"assertion":[{"value":"2020-02-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}